Navigation Links
MannKind Corporation Reports Third Quarter Financial Results
Date:11/5/2008

l forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

(Tables to follow)

MANNKIND CORPORATION

(A Development Stage Company)

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands except per share data)

Cumulative period

from February 14,

1991 (date of

Three months ended Nine months ended inception) to

September 30, September 30, September 30,

2008 2007 2008 2007 2008

Revenue $- $- $20 $10 $2,988

Operating

expenses:

Research and

development 55,645 64,825 181,665 190,093 928,705

General and

administrative 13,435 10,744 42,365 38,207 232,864

In-process

research and

development costs - - - - 19,726

Goodwill

impairment - - - - 151,428

Total operating

expenses 69,080 75,569 224,030 228,300 1,332,723

Loss from

operations (69,080) (75,569) (224,010) (228,290) (1,329,735)

Other income

(expense) (7) 62 (7) 158 (1,888)

Interest expense

on note

payable to

principal

stockholder - - -
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. MannKind Corporation to Host Webcast Analyst Day September 16, 2008
2. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
3. MannKind to Present at the Cowen and Company Healthcare Conference
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind Corporation Reports Third Quarter Financial Results
6. MannKind to Present at Upcoming Conferences
7. MannKind Announces New $350 Million Credit Facility
8. Providence Service Corporation Releases Third Quarter Results
9. United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results
10. Psychemedics Corporation Announces Third Quarter Results
11. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis Gilroy, ... of the American Telemedicine Association (ATA). The ... a mission to promote professional, ethical and equitable ... technology. , “Both Naomi Fried and Alexis Gilroy, ... and are well known experts in their respective ...
(Date:7/30/2014)... -- Clues to whether a person is at risk for ... study suggests. Chemical changes to a gene involved in ... thoughts and behaviors, the study,s authors explained. Spotting those changes ... patient,s risk for suicide, they said. "Suicide is a ... in our prevention efforts because we have no consistent way ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... is available in French . ... Claude Gronfier (Inserm Unit 846: Stem Cell and Brain ... under real conditions on the body clocks of members ... have shown that a particular kind of artificial light ... correctly synchronised despite the absence of sunlight. The full ...
(Date:7/30/2014)... Children diagnosed with depression as preschoolers are likely to ... new research shows. , Depressed preschoolers were 2.5 times ... and middle school than kids who were not depressed ... University School of Medicine in St. Louis. , Their ... American Journal of Psychiatry . , "It,s the ...
Breaking Medicine News(10 mins):Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3
... Some complications may occur in children receiving cochlear implants, ... area and inner ear malformation, according to a report ... & Neck Surgery , one of the JAMA/Archives journals. ... provide a sense of sound to individuals who are ...
... cartilage to plates made of the resorbable material polydioxanone ... the thin cartilage separating the two airways, according to ... of Facial Plastic Surgery , one of the JAMA/Archives ... deviated septum, is not always possible because the surgical ...
... simple question of male patients , MONDAY, Jan. 18 ... sign that a man might be at increased risk ... long-running study indicates. , "We saw that adjusting for ... erectile function still had a 40 percent increased risk," ...
... as well as other meds, study finds, , MONDAY, ... psoriasis is rising faster than inflation, says a U.S. ... more than traditional systemic therapies. , The researchers created ... systemic therapy for psoriasis, a chronic autoimmune skin disease ...
... benefits vs. risks, researchers say , MONDAY, Jan. 18 (HealthDay ... most of the five percent of Americans who are very ... researchers at the University of Cincinnati, concluded that the benefits ... for most people who are morbidly obese, which is defined ...
... to contribute to heart disease, researchers say , MONDAY, Jan. ... restaurants are immersed in corn-based oil -- usually considered the ... to the authors of a new study. , Corn oil ... heart disease. , This type of oil is also ...
Cached Medicine News:Health News:Complications common, often linked to trauma in children receiving cochlear implants 2Health News:Synthetic, dissolving plates ease repairs of nasal septum defects 2Health News:Erectile Dysfunction Predicts Heart Disease 2Health News:Cost of Psoriasis Drugs Rising Faster Than Others 2Health News:For Very Obese, Gastric Bypass May Extend Life 2Health News:For Very Obese, Gastric Bypass May Extend Life 3Health News:Most Fast-Food French Fries Cooked in Unhealthiest Oil 2Health News:Most Fast-Food French Fries Cooked in Unhealthiest Oil 3
(Date:7/30/2014)... and PARIS , July ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia ... reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at ... is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase ...
(Date:7/30/2014)...  Packaging Coordinators, Inc. (PCI) is pleased to announce ... Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered in ... United Kingdom and operates regional offices ... Tokyo , Japan. Penn Pharma offers both ... dosage form manufacturing, as well as Clinical Packaging, Labeling, ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
8 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.6 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The Meridian Microruptor V Nd: YAG laser system is indicated for posterior capsulotomy, peripheral iridotomy, and pupillary membranectomy procedures....
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
Medicine Products: